Evolus (EOLS) Stock Forecast & Price Target

Evolus is showing strong fundamental momentum, with Q3 revenue of $78.0M rising 13% year over year and adjusted EBITDA turning positive for a fourth consecutive quarter at $1.2M, while the U.S. aesthetics market remains healthy with toxins growing mid- to high-single digits and fillers stable. Its outlook is further supported by Jeuveau’s established mid-teens U.S. share, Evolysse’s early traction with more than 4,500 customers and 17% penetration, and a >70% cumulative reorder rate that signals durable demand and expanding account depth. Management’s tightened FY26 non-GAAP opex guidance, reaffirmed 2028 revenue target of $450M-$500M, and a pipeline of additional launches, including Evolysse Sculpt and Evolysse Lips, strengthen confidence in sustained double-digit growth and improving profitability.

Evolus is facing a weaker fundamental outlook as its outyear revenue estimates are modestly reduced to reflect more conservative toxin market growth assumptions, signaling slower expansion in its core injectable aesthetics business. Although the impact on adjusted EBITDA estimates is minimal, the company still faces meaningful downside from deteriorating consumer spending, inconsistent commercial execution, competition, pricing pressure, and a slower-than-expected ramp of Evolysse. Additional risks from supply chain challenges, potential tariffs, regulatory delays, higher-than-expected operating expenses, and negative clinical data updates further cloud visibility across its U.S., Canada, Europe, and Australia operations.